BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19

BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2,...

Full description

Bibliographic Details
Main Authors:	Rui-Ru Ji, Yajin Qu, Hua Zhu, Yumei Yang, Annette B. Vogel, Ugur Sahin, Chuan Qin, Aimin Hui
Format:	Article
Language:	English
Published:	MDPI AG 2021-04-01
Series:	Vaccines
Subjects:	SARS-CoV-2 COVID-19 mRNA vaccine efficacy immunogenicity challenge study
Online Access:	https://www.mdpi.com/2076-393X/9/4/324

Similar Items

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany
by: Tatjana Schwarz, et al.
Published: (2021-08-01)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
by: Takeshi Terashima
Published: (2021-01-01)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
by: Fulvia Pimpinelli, et al.
Published: (2021-07-01)

Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors
by: Massimo Cugno, et al.
Published: (2021-09-01)

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
by: Emanuel Zitt, et al.
Published: (2021-06-01)

Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers
by: Salvatore Zaffina, et al.
Published: (2021-06-01)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
by: Michael Jahn, et al.
Published: (2021-04-01)

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
by: Ahmed Zaqout, et al.
Published: (2021-07-01)

BNT162b2 COVID-19 Vaccine Hesitancy among Parents of 4023 Young Adolescents (12–15 Years) in Qatar
by: Sarah Musa, et al.
Published: (2021-09-01)

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines
by: Alexandre Vallée, et al.
Published: (2021-08-01)

Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
by: Luca Coppeta, et al.
Published: (2021-08-01)

Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people
by: Helen Parry, et al.
Published: (2021-08-01)

BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents
by: Bernd Jahrsdörfer, et al.
Published: (2021-09-01)

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
by: Fulvia Pimpinelli, et al.
Published: (2021-05-01)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Xin Rong Lim, et al.
Published: (2021-08-01)

T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity
by: Jose L Casado, et al.
Published: (2021-01-01)

First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers
by: Luca Coppeta, et al.
Published: (2021-06-01)

Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL
by: Lien Van Hoecke, et al.
Published: (2018-10-01)

Comparative effectiveness of BNT162B2 and mRNA-1273 vaccines in U.S. Veterans
by: Casas, J.P, et al.
Published: (2022)

Acute myocarditis following administration of BNT162b2 vaccine
by: Mhd Baraa Habib, et al.
Published: (2021-01-01)

BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees
by: Ahmed N. Alghamdi, et al.
Published: (2021-10-01)

Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies
by: Donato Amodio, et al.
Published: (2021-10-01)

Impact of Age and Sex on Antibody Response Following the Second Dose of COVID-19 BNT162b2 mRNA Vaccine in Greek Healthcare Workers
by: Niki Vassilaki, et al.
Published: (2021-08-01)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
by: Polack, Fernando P, et al.
Published: (2021)

Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients
by: Cristina Bergamaschi, et al.
Published: (2021-08-01)

Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine
by: B Roca, et al.
Published: (2021-01-01)

Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine
by: Chiara Agrati, et al.
Published: (2021-06-01)

Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers
by: Renuka A.K. Kadali, et al.
Published: (2021-05-01)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
by: Timothy A. Bates, et al.
Published: (2021-08-01)

Effectiveness of BNT162B2 Vaccine against Critical Covid-19 in Adolescents
by: Bhumbra, S.S, et al.
Published: (2022)

Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers
by: Antonella d'Arminio Monforte, et al.
Published: (2021-06-01)

Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection
by: Ilaria Vicenti, et al.
Published: (2021-07-01)

Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals
by: Yosuke Hirotsu, et al.
Published: (2021-08-01)

Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany
by: Manuela A. Hoffmann, et al.
Published: (2021-08-01)

Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
by: Louise Benning, et al.
Published: (2021-08-01)

A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population
by: Chinonyerem O. Iheanacho, et al.
Published: (2021-08-01)

Fatal Neurodissemination and SARS-CoV-2 Tropism in K18-hACE2 Mice Is Only Partially Dependent on hACE2 Expression
by: Balasuriya, U.B.R, et al.
Published: (2022)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021-08-01)

Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence?
by: Giulia Renisi, et al.
Published: (2021-09-01)

Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech
by: Yusuke Okada, et al.
Published: (2021-09-01)